| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
Purity: =99.41%
| Targets |
Ghrelin receptor (or GH secretagogue receptor, GHSR)
Ipamorelin targets the ghrelin receptor, also known as the growth hormone secretagogue receptor (GHS-R1a). It is a selective agonist of the GHS receptor. It binds to COS-7 cells expressing GHS-R1a with a Ki of 63.4 nM. By activating this receptor, it stimulates the release of growth hormone from the pituitary gland. |
|---|---|
| ln Vitro |
Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) and a ghrelin mimetic with growth hormone (GH) releasing activity. Ipamorelin mimics ghrelin and binds to the ghrelin receptor (or GH secretagogue receptor, GHSR) in the brain, thereby selectively stimulating the release of GH from the pituitary gland. This results in increased plasma GH levels, which would affect many biological processes. Besides its presence in the brain, GHSR can also be found in the gastrointestinal tract, heart, lung, liver, kidney, pancreas, adipose tissue and immune cells. Unlike other GH releasing peptides, ipamorelin only stimulates GH release in a manner very similar to that of growth hormone releasing hormone.
Ipamorelin is a potent and selective agonist of the ghrelin receptor. It binds to COS-7 cells expressing GHS-R1a with a Ki of 63.4 nM. It stimulates GH release via a GHRP-like receptor. Its activity has been confirmed in various in vitro binding and functional assays. It induces longitudinal bone growth in rats. |
| ln Vivo |
IPAMORELIN is a Protein drug with a maximum clinical trial phase of II and has 1 investigational indication.
Ipamorelin is a growth hormone secretagogue that stimulates the release of growth hormone in vivo. It induces longitudinal bone growth in rats. It has been investigated for the treatment of ileus and gastrointestinal dysmotility. Its ability to stimulate GH release makes it a potential therapeutic agent for growth hormone deficiency and other conditions. |
| Enzyme Assay |
The primary in vitro assay for Ipamorelin is a radioligand binding assay using cells expressing GHS-R1a. The compound's ability to displace a labeled ligand is measured to determine its Ki value. Functional assays measure its ability to stimulate GH release from pituitary cells in culture.
|
| Cell Assay |
Cellular assays for Ipamorelin involve treating cells expressing GHS-R1a, such as COS-7 cells, with the compound and measuring its effects on receptor-mediated signaling. Its ability to stimulate GH release can be assessed in primary pituitary cell cultures by measuring GH levels in the culture supernatant.
|
| Animal Protocol |
In vivo animal experiments for Ipamorelin have been conducted in rats to assess its effects on growth hormone release and bone growth. The compound is administered, and its effects on serum GH levels and longitudinal bone growth are measured. Its effects on gastrointestinal motility have also been investigated.
|
| ADME/Pharmacokinetics |
Ipamorelin has a molecular weight of 711.89 g/mol and a molecular formula of C38H49N9O5. It is a pentapeptide growth hormone secretagogue. It is typically used as a research reagent. Its purity is typically ≥98%. The compound is also known as NNC-26-0161.
|
| Toxicity/Toxicokinetics |
The toxicological profile of Ipamorelin is not extensively detailed in the provided sources. As a research compound, it is not intended for human use. Standard safety precautions should be followed when handling. Its safety would need to be established through preclinical studies if it were to be developed for therapeutic applications.
|
| References |
[1]. Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin. Drug Test Anal. 2015 Oct;7(10):919-25.
|
| Additional Infomation |
Iparrelin has been investigated for the treatment of intestinal obstruction. Iparrelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2), a growth hormone-releasing peptide analog with growth hormone (GH)-releasing activity. Iparrelin mimics GH-releasing peptide and binds to the GH-releasing peptide receptor (or growth hormone secretagogue receptor, GHSR) in the brain, thereby selectively stimulating the pituitary gland to release growth hormone. This leads to elevated plasma growth hormone levels, which in turn affect many biological processes. Besides the brain, GHSR is also found in the gastrointestinal tract, heart, lungs, liver, kidneys, pancreas, adipose tissue, and immune cells. Unlike other GH-releasing peptides, iparelin stimulates growth hormone release in a manner very similar to GH-releasing hormone.
Ipamorelin (NNC-26-0161) is a pentapeptide growth hormone secretagogue and selective agonist of the ghrelin receptor. It stimulates the release of growth hormone from the pituitary gland and induces longitudinal bone growth in rats. It has been investigated for the treatment of ileus and gastrointestinal dysmotility. It is available from various chemical suppliers for research purposes. |
| Molecular Formula |
C38H49N9O5
|
|---|---|
| Molecular Weight |
711.8530
|
| Exact Mass |
711.385
|
| Elemental Analysis |
C, 64.12; H, 6.94; N, 17.71; O, 11.24
|
| CAS # |
170851-70-4
|
| PubChem CID |
9831659
|
| Sequence |
Aib-His-D-2-Nal-D-Phe-Lys-NH2;
H-Aib-His-D-2Nal-D-Phe-Lys-NH2;
alpha-methyl-alanyl-L-histidyl-3-(2-naphthyl)-D-alanyl-D-phenylalanyl-L-lysinamide
|
| SequenceShortening |
XHXFK
|
| Appearance |
Powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
1185.5±65.0 °C at 760 mmHg
|
| Flash Point |
670.7±34.3 °C
|
| Vapour Pressure |
0.0±0.3 mmHg at 25°C
|
| Index of Refraction |
1.624
|
| LogP |
1.72
|
| Hydrogen Bond Donor Count |
8
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
19
|
| Heavy Atom Count |
52
|
| Complexity |
1200
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
O=C(C([H])(C([H])([H])C1C([H])=C([H])C2=C([H])C([H])=C([H])C([H])=C2C=1[H])N([H])C(C([H])(C([H])([H])C1=C([H])N=C([H])N1[H])N([H])C(C(C([H])([H])[H])(C([H])([H])[H])N([H])[H])=O)=O)N([H])C([H])(C(N([H])C([H])(C(N([H])[H])=O)C([H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H])=O)C([H])([H])C1C([H])=C([H])C([H])=C([H])C=1[H]
|
| InChi Key |
NEHWBYHLYZGBNO-BVEPWEIPSA-N
|
| InChi Code |
InChI=1S/C38H49N9O5/c1-38(2,41)37(52)47-32(21-28-22-42-23-43-28)36(51)46-31(20-25-15-16-26-12-6-7-13-27(26)18-25)35(50)45-30(19-24-10-4-3-5-11-24)34(49)44-29(33(40)48)14-8-9-17-39/h3-7,10-13,15-16,18,22-23,29-32H,8-9,14,17,19-21,39,41H2,1-2H3,(H2,40,48)(H,42,43)(H,44,49)(H,45,50)(H,46,51)(H,47,52)/t29-,30+,31+,32-/m0/s1
|
| Chemical Name |
(S)-6-amino-2-((R)-2-((R)-2-((S)-2-(2-amino-2-methylpropanamido)-3-(1H-imidazol-4-yl)propanamido)-3-(naphthalen-2-yl)propanamido)-3-phenylpropanamido)hexanamide
|
| Synonyms |
NNC-26-0161; NNC 26-0161; Ipamorelin; 170851-70-4; NNC-26-0,161; Y9M3S784Z6; Aib-His-D-2-Nal-D-Phe-Lys-NH2; NNC26-0161; NNC-260161; NNC 260161; NNC260161.
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.4048 mL | 7.0240 mL | 14.0479 mL | |
| 5 mM | 0.2810 mL | 1.4048 mL | 2.8096 mL | |
| 10 mM | 0.1405 mL | 0.7024 mL | 1.4048 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA